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The transcription factor Pax5 is a critical regulator of B lymphocyte commitment and identity. In this
issue of Immunity, Schebesta et al. (2007) demonstrate how Pax5 activates 170 different genes
involved in B cell signaling, adhesion, migration, and maturation.The control of cell-fate determination
is a function of lineage-specific
transcription factors (reviewed in
Rothenberg, 2007). Multipotential
progenitor cells respond to environ-
mental cues that direct progressively
restricted patterns of gene expression
and limit developmental potential.
Through this process, a cell’s identity
is fixed within a single lineage. Much
of what we know concerning the
process of lineage commitment is
due to studies of the gene encoding
Paired box gene 5 (Pax5). Pax5 was
first reported to be critical for the
expression of multiple genes in early
B cells, including key components of
the pre-B and mature B cell receptors
(pre-BCR and BCR). Pax5-deficient
mice generated in the Busslinger labo-
ratory revealed the absolute depen-
dence of B cell development on Pax5
(Urba´nek et al., 1994). In the absence
of Pax5, developmental arrest oc-
curred at a pro-B cell-like stage. B
cell progenitors lacking Pax5 com-
pleted immunoglobulin (Ig) heavy-
chain gene rearrangements ineffi-
ciently and lacked light-chain gene
rearrangements. Analysis of putative
target genes in the absence of Pax5
suggested that it functions as both an
activator and a repressor of transcrip-
tion. Thus, Pax5 is critical for expres-
sion of the B cell lineage-specific
program and Ig gene rearrangements
essential for humoral immunity.
Surprisingly, pro-B cells from
Pax5/ mice demonstrated increased
developmental plasticity (Nutt et al.,
1999). In response to reprogramming8 Immunity 27, July 2007 ª2007 Elseviersignals in vitro and in vivo, B cell
progenitors lacking Pax5 were able to
differentiate into other hematopoietic
lineages including myeloid cells and
macrophages, granulocytes, osteo-
clasts, natural killer cells, and T cells.
The molecular basis of this failure in lin-
eage commitment derives from Pax5’s
ability to repress genes and signaling
pathways (i.e., Notch1) required for de-
velopment of other lineages. This
mechanism is incompletely under-
stood, but in certain contexts, Pax5 re-
cruits corepressors (Groucho) that me-
diate transcriptional silencing. The
scope of this repression was recently
addressed via microarray technolo-
gies. Delogu and colleagues identified
110 Pax5-repressed genes that en-
code proteins involved in cell-cell com-
munication, adhesion and migration,
nuclear processes, and cell metabo-
lism (Delogu et al., 2006). Some of
these genes (e.g.,Cd28) are expressed
prior to Pax5 expression and are re-
expressed after Pax5 turns off during
differentiation into plasma cells.
Clearly, Pax5 has important roles in
limiting developmental potential, but
the full extent of Pax5’s contributions
to generating B cell identity has yet to
be defined. In an article in this issue of
Immunity, Schebesta and colleagues
(Schebesta et al., 2007) used state-
of-the-art microarrays and extensive
validation to generate an unprece-
dented view of regulatory circuits in B
cells. Remarkably, comparisons be-
tween patterns of genes expressed in
pro-B cells of Pax5+/+ and Pax5/
mice demonstrated that the activationInc.of 170 different genes is dependent
on Pax5. Stringent analysis of the
data confirmed the regulation of previ-
ously identified target genes of Pax5
such as Mb1, Cd19, Blnk, Bcl2l1 (bcl-
xL), and Igk germline transcripts. The
new data demonstrated that Pax5 reg-
ulates a diverse set of genes encoding
cell-surface receptors, signal trans-
ducers, and nuclear proteins including
downstream regulators that extend the
B cell-specific regulatory network.
These nuclear proteins include Spib,
Irf4, Irf8, Bach2, and Ikzf3 (Aiolos),
which regulate germinal-center B cell
formation. The data also confirmed
the recently identified reciprocal regu-
latory circuit between Early B cell
Factor (EBF) and Pax5 (Roessler
et al., 2007). Other Pax5 targets
include genes involved in cell-cycle
regulation, protein trafficking, the
cytoskeleton, and metabolic path-
ways. Furthermore, this work revealed
a cohort of 15 Pax5-dependent genes
that may impact cell migration and
adhesion. In total, the data suggest
a ‘‘hands on’’ role for Pax5 in regulating
the expression of genes, which
impacts almost every aspect of B cell
development and function (Figure 1).
To determine whether the continual
presence of Pax5 is necessary for the
maintenance of target gene transcrip-
tion in committed pro-B cells, the
authors used a model in which Pax5
genes are deleted in the presence of
a Cre-estrogen receptor (Cre-ER)
fusion protein, which allows for regula-
tion of Cre-mediated recombination by
estrogen. After Pax5 gene deletion,
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PreviewsFigure 1. Regulation of B Cell Differentiation and Function by Pax5
Transcription factors (PU.1, Ikaros, E2A, EBF, and Foxp1) chaperone uncommitted progenitors into the B cell pathway; however, Pax5 is required for
B cell lineage commitment. An important function of Pax5 is the repression of non-B lineage genes in B cells, which are promiscuously expressed in
Pax5’s absence. The lack of Pax5 results in increased plasticity, as demonstrated by the ability of Pax5-deficient pro-B cells to differentiate into cell
types indicated at left. Expression of Pax5 in normal pro-B cells and progressive stages of development activates 170 genes involved in the processes
indicated in the green box. Pax5 is also essential for activating expression of transcription factors necessary for germinal-center formation. As the
gatekeeper of terminal B cell differentiation, downregulation of Pax5 is required to turn off expression of the early B cell program and to allow expres-
sion of the plasma cell program.many of the newly identified target
genes were downregulated with kinet-
ics similar to that of known Pax5 tar-
gets (e.g., Cd19 and Blnk). Extending
previous studies that demonstrated
the loss of identity of mature B cells
in the absence of Pax5 (Horcher
et al., 2001), elimination of Pax5 in
the same population by means of
Cd19-Cre verified its regulation of an
extensive set of genes. Thus, Pax5 is
required continuously for maintenance
of the B cell program from early stages
in the bone marrow through mature
stages of development in the periph-
ery. However, silencing Pax5 is critical
for differentiation into plasma cells,
which do not express Pax5. In the
paper by Schebesta et al. (2007), the
authors used quantitative RT-PCR
analysis of transcripts to define pat-
terns of target gene expression in
pure populations of plasma cells.
Overall, approximately half of the
Pax5-activated genes were downre-
gulated in plasma cells. Interestingly,
a number of genes, including Nedd9,
Blnk, and Irf4, continued to be
expressed in the absence of Pax5.
These genes may be targets of a ‘‘hit
and run’’ mode of action in which
Pax5 turns genes on in early B cell
progenitors but is not required formaintaining their expression at later
stages of development (Rothenberg,
2007). Furthermore, downregulation
of Pax5 is sufficient for mature B cells
to become preplasmablasts (Kallies
et al., 2007). The data support the
hypothesis that terminal differentiation
is initiated by the silencing of Pax5.
Among hematopoietic cells, Pax5 is
expressed solely in the B cell lineage
(Pax5 is also expressed in the develop-
ing midbrain). The question arises: are
all Pax5-activated genes expressed
exclusively in B cells? By using quanti-
tative PCR analysis of 32 Pax5-regu-
lated transcripts, the authors demon-
strated that 15 of these transcripts are
largely restricted to B cells. Of these,
half were expressed in all stages of de-
velopment coincident with Pax5, while
the others were confined to early pro-B
and pre-B cell stages. The remaining
17 genes were expressed in B cells
and in non-B lineage cells that lack
Pax5. This suggests the presence of
factors in non-B hematopoetic cells
that functionally substitute for Pax5.
Regulatory networks include both
direct and indirect circuits. Direct
regulation increases transcription
through direct binding of factors to
promoters and enhancers. Alterna-
tively, direct gene targets may encodeImmother transcription factors that in turn
activate indirect targets. To identify
gene subsets that are directly or indi-
rectly regulated by Pax5, Pax5–/–
pro-B cells were reconstituted with
a previously characterized Pax5-ER
fusion protein. In response to Pax5-
ER and estrogen, 17 gene targets
were activated. To determine whether
these genes are direct targets of
Pax5, pre-existing Pax5-ER protein
was activated by estrogen in the pres-
ence of cycloheximide, which blocks
new protein synthesis. 11 genes in-
cluding Ikzf3, Irf4, and Irf8 were tran-
scribed and confirmed as direct tar-
gets of Pax5.
How does Pax5 activate target
genes? Via chromatin immunopre-
cipitation-coupled DNA microarray
analysis (ChIP-on-chip), the authors
demonstrated Pax5-dependent
enrichment of active histone marks
including acetylated (H3K9Ac) and
methylated (H3K4 me2 and H3K4
me3) histone H3 at promoters and
just downstream of nine different
target genes. H3K4 me3 was exclu-
sively detected at 50 ends of genes
coinciding with promoter elements. It
was noted that enrichment of the three
active marks is an effective predictor
of the locations of promoters. Theunity 27, July 2007 ª2007 Elsevier Inc. 9
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sis by correlating active marks with
known regulatory modules within the
Rag1 and Rag2 loci. Notably, target
genes in Pax5/ pro-B cells exhibited
greatly reduced active histone marks
relative to wild-type Pax5 pro-B cells.
As suspected, the presence or
absence of active histone marks cor-
related with Pax5 binding at promoters
and enhancers. Taken together, these
data confirm that transcriptional acti-
vation by Pax5 is a consequence of
its DNA binding, which in turn gener-
ates active chromatin domains at
regulatory modules of target genes.
Although new functions of Pax5 (i.e.,
the control of cell adhesion and migra-
tion) are elucidated by this work, other
roles of Pax5 remain to be clarified.
The recent genome-wide analysis of
genetic alterations in acute lympho-
blastic leukemia patients identified
Pax5 haploinsufficiency as a contri-
butor to pathogenesis in humans10 Immunity 27, July 2007 ª2007 Elsevie(Mullighan et al., 2007). These data,
together with reports linking overex-
pression of Pax5 with lymphomagene-
sis, suggest that a narrow range of
Pax5 concentrations is critical for
normal B cell lymphopoiesis and
homeostasis. Another major question
concerns how Pax5 induces V-to-DJ
rearrangements via contraction of Ig
heavy-chain loci (Fuxa et al., 2004). In
conclusion, the data reported by
Schebesta et al. (2007) not only place
Pax5 at the center of an exceedingly
complex regulatory network, but also
provide a framework for addressing
additional problems in normal and ab-
normal B cell biology.
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